Creating Better Medicines through Better Conjugation

Clinical-stage biopharmaceutical company Ambrx leverages its site-specific bioconjugation technology through partnerships.

Clinical-stage biopharmaceutical company Ambrx leverages its site-specific bioconjugation technology through partnerships to bring drugs with enhanced stability and bioactivity to market.

Read this article

from BioPharm International’s 2013 Innovation Updates and Strategies eBook.

Articles in this issue

almost 12 years ago

Article

Recovering Patent Life with Patent Term Extension

almost 12 years ago

Article

Strategic Outsourcing in Clinical Development

almost 12 years ago

Article

Leveraging Development Strengths Drives Therapies to Market

almost 12 years ago

Article

Driving Innovation in Biopharmaceuticals

almost 12 years ago

Article

Crowdfunding Biopharmaceutical Innovation

almost 12 years ago

Article

Restructuring for Biopharmaceutical Success

Newsletter

Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.

Subscribe Now!